Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II Clinical Study

NCT04126993 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT04126993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04126993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II Clinical Study
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2019
Completion date
December 31, 2020
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma